Receptor tyrosine kinases as rational targets for prostate cancer treatment: Platelet-derived growth factor receptor and imatinib mesylate

Urology

Volumn 60, Issue 3 SUPPL. 1, 2002, Pages 115-121

  George, Daniel J ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; GROWTH FACTOR; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CELL GROWTH; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG EFFICACY; DRUG TARGETING; HUMAN; METASTASIS; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TOXICITY;

EID: 0036755403     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01589-3     Document Type: Article

References (36)

1. Druker B.J., Talpaz M., Debra M.D., et al. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 344:2001;1031-1037.
2. Druker B.J., Sawyers C.L., Kantarjian H., et al. Activity of a specific inhibitor of BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 244:2001;1038-1042.
3. Joensuu H., Roberts P.J., Sarlomo-Rikala M., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 344:2001;1052-1056.
4. Blanke C.D., von Mehren M., Joensuu H., et al. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients (Pts) with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing C-KIT (CD117). Abstracts of the 2001 Annual Meeting of American Society of Clinical Oncology. ASCO. 20:2001;1a. Abstract 1.
5. Van Oosterom A.T., Judson I., Verweij J., et al. STI 571, an active drug in metastatic gastrointestinal stromal tumors (GIST), an EORTC phase I study. Abstracts of the 2001 Annual Meeting of American Society of Clinical Oncology. ASCO. 20:2001;1a. Abstract 2.
6. Djakiew D. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate. 42:2000;150-160.
7. Vogelstein B., Kinzler K.W. The multistep nature of cancer. Trends Genet. 9:1993;138-141.
8. Barton J., Blackledge G., Wakeling A. Growth factors and their receptors new targets for prostate cancer therapy . Urology. 58:(suppl 1):2001;114-122.
9. Betsholts C., Johnsson A., Heldin C.-H., et al. cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumor cell lines. Nature. 323:1986;226-232.
10. Li X., Ponten A., Aase K., et al. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nature Cell Biol. 2:2000;302-309.
11. Deuel T.F. Polypeptide growth factors roles in normal and abnormal growth . Annu Rev Cell Biol. 3:1987;443-492.
12. Östman A., Heldin C.-H. Involvement of platelet-derived growth in disease development of specific antagonists . Adv Cancer Res. 80:2001;1-38.
13. Grotendorst G.R., Martin G.R., Pencev D., et al. Stimulation of granulation tissue formation by platelet-derived growth factor in normal and diabetic rats. J Clin Invest. 76:1985;2323-2339.
14. Sprugel K.-H., McPherson J.M., Clowes A.W., et al. Effects of growth factors in vivo. I. Cell ingrowth into porous subcutaneous chambers. Am J Pathol. 129:1987;601-613.
15. Crosby J.R., Seifert R.A., Soriano P., et al. Chimaeric analysis reveals role of PDGF receptors in all muscle lineages. Nat Genet. 18:1998;385-388.
16. Lindahl P., Johansson Levéen P., et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 277:1997;242-245.
17. Fleming T.P., Saxena A., Clark W.C., et al. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res. 52:1992;4550-4553.
18. Guha A., Dashner K., Black P.M., et al. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer. 60:1995;168-173.
19. Hermanson M., Funa K., Hartman M., et al. Platelet-derived growth factor and its receptors in human glioma tissue expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops . Cancer Res. 52:1992;3213-3219.
20. Black P.M., Carroll R., Glowacka D., et al. Platelet-derived growth factor expression and stimulation in human meningiomas. J Neurosurg. 81:1994;388-393.
21. Figarella-Branger D., Vagner-Capodano A.M., Bouillot P., et al. Platelet-derived growth factor (PDGF) and receptor (PDGFR) expression in human meningiomas correlations with clinicopathological features and cytogenetic analysis . Neuropathol Appl Neurobiol. 20:1994;439-447.
22. Todo T., Adams E.F., Fahlbusch R., et al. Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor. J Neurosurg. 84:1996;852-858.
23. Barnhill R.L., Xiao M., Graves D., et al. Expression of platelet-derived growth factor (PDGF)-A, PDGF-B and the PDGF-alpha receptor, but not the PDGF-beta receptor, in human malignant melanoma in vivo. Br J Dermatol. 135:1996;898-904.
24. Chaudhry A., Papanicolaou V., Öberg K., et al. Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Res. 52:1992;1006-1012.
25. Henrikson R., Funa K., Wilander E., et al. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res. 53:1993;4550-4554.
26. Ebert M., Yokoyama M., Friess H., et al. Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int J Cancer. 62:1995;529-535.
27. Chung C.K., Antoniades H.N. Expression of c-sis/platelet-derived growth factor B, insulin-like growth factor I, and transforming growth factor alpha messenger RNAs and their respective receptor messenger RNAs in primary human gastric carcinomas in vivo studies with in situ hybridization and immunocytochemistry . Cancer Res. 52:1992;3453-3459.
28. Antoniades H.N., Galanopoulos T., Neville-Golden J., et al. Malignant epithelial cells in primary human lung carcinomas coexpress in vivo platelet-derived growth factor (PDGF) and PDGF receptor mRNAs and their protein products. Proc Natl Acad U S A. 89:1992;3942-3946.
29. Fudge K., Wang C.Y., Stearns M.E. Immunohistochemistry analysis of platelet-derived growth factor A and B chain and platelet-derived growth factor α and β receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas. Mod Pathol. 7:1994;549-554.
30. Fudge K., Bostwick D.G., Stearns M.E. Platelet-derived growth factor A and B chains and the α and β receptors in prostatic intraepithelial neoplasia. Prostate. 29:1996;282-286.
31. Chott A., Zijie S., Morganstern D., et al. Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol. 155:1999;1271-1279.
32. Ko Y.-J., Small E.J., Kabbinavar F., et al. A Multi-institutional phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res. 7:2001;800-805.
33. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med. 2:1996;561-566.
34. Buchdunger E., Zimmermann J., Mett H., et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56:1996;100-104.
35. Buchdunger E., Cioffi C.L., Law N., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 295:2000;139-145.
36. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998 280:1998;969-974.